INTRODUCTION: A HISTORICAL PERSPECTIVE

At the time of implementation of human allogenic lung transplantation (LTx) by James Hardy in 1963, survival was limited to a maximum of weeks due to surgical and infectious complications. It took until 1971 for a posttransplant survival of 10 months to be reported by Derom et al. Following several episodes of severe acute rejection, 6 months posttransplant their patient developed irreversibly decreased values of forced expiratory volume in 1 second (FEV₁) and FEV₁/forced vital

MINIREVIEW

When tissue is the issue: A histological review of chronic lung allograft dysfunction

Stijn E. Verleden¹,² | Jan Von der Thüsen³ | Antoine Roux⁴ | Emily S. Brouwers²,⁵ | Peter Braubach²,⁵ | Mark Kuehnel²,⁵ | Florian Laenger²,⁵ | Danny Jonigk²,⁵

Although chronic lung allograft dysfunction (CLAD) remains the major life-limiting factor following lung transplantation, much of its pathophysiology remains unknown. The discovery that CLAD can manifest both clinically and morphologically in vastly different ways led to the definition of distinct subtypes of CLAD. In this review, recent advances in our understanding of the pathophysiological mechanisms of the different phenotypes of CLAD will be discussed with a particular focus on tissue-based and molecular studies. An overview of the current knowledge on the mechanisms of the airway-centered bronchiolitis obliterans syndrome, as well as the airway and alveolar injuries in the restrictive allograft syndrome and also the vascular compartment in chronic antibody-mediated rejection is provided. Specific attention is also given to morphological and molecular markers for early CLAD diagnosis or histological changes associated with subsequent CLAD development. Evidence for a possible overlap between different forms of CLAD is presented and discussed. In the end, “tissue remains the (main) issue,” as we are still limited in our knowledge about the actual triggers and specific mechanisms of all late forms of posttransplant graft failure, a shortcoming that needs to be addressed in order to further improve the outcome of lung transplant recipients.

KEYWORDS
biopsy, bronchiolitis obliterans (BOS), lung (allograft) function/dysfunction, lung transplantation/pulmonology, pathology/histopathology, rejection: antibody-mediated (ABMR), rejection: chronic, translational research/science

1 INTRODUCTION: A HISTORICAL PERSPECTIVE

At the time of implementation of human allogenic lung transplantation (LTx) by James Hardy in 1963, survival was limited to a maximum of

Abbreviations: AFOP, acute fibrinoid organizing pneumonia; BO, bronchiolitis obliterans; BOS, bronchiolitis obliterans syndrome; cAMR, chronic antibody-mediated rejection; CLAD, chronic lung allograft dysfunction; DAD, diffuse alveolar damage; DSA, donor-specific antibodies; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; HSCT, hematopoietic stem cell transplantation; ISHLT, International Society for Heart and Lung Transplantation; LTx, lung transplantation; PPFE, pleuroparenchymal fibroelastosis; RAS, restrictive allograft syndrome.
capacity (FVC), suggestive of an obstructive airway disease. At autopsy, the bronchi displayed various degrees of fibrotic stenosis with infiltration by inflammatory cells. These findings from our current perspective represent the first described case of bronchiolitis obliterans (BO) as a manifestation of chronic lung allograft dysfunction (CLAD).

However, it took more than a decade until BO as an entity was formally defined by Epler and Colby as a fibrosing inflammatory process involving the terminal and respiratory bronchioles. At the time BO was thought to arise either idiopathically or following exposure, infection, or in the context of connective tissue disease. Subsequently, BO was also described in association with progressive obstructive pulmonary function defects following bone marrow transplantation and in more patients after LTx. Indeed, in biopsies and autopsies from 4 LTx recipients, Burke et al demonstrated extensive BO in 3, again associated with a progressive decline in pulmonary function, but they also found varying degrees of interstitial and pleural fibrosis. This report in conjunction with similar observations by other groups led to the acceptance of BO as the morphological correlate of what was at the time termed “chronic rejection.” Subtotal and total airway obliteration as well as active and inactive remodeling based on the degree of lymphocytic airway inflammation were further used to categorize BO. At the time, it was already recognized that transbronchial biopsies generally have a low sensitivity to detect BO lesions due to the latter’s heterogeneous and mostly peripheral distribution. Therefore, bronchiolitis obliterans syndrome (BOS), a clinical entity solely based on lung function tests, was introduced with 2 subcategories based on confirmation of the clinical diagnosis by histopathology. In later revisions, the relevance of histology faded further due to the aforementioned low sensitivity of biopsies, and BOS became a strictly clinical diagnosis based on the FEV1. At that point, histology was mostly used to rule out other posttransplant complications, such as infection or acute cellular rejection. This definition was first challenged by the identification of a group of patients that recovered their FEV1 following long-time treatment with azithromycin and on the histological level showed persistent chronic airway inflammation (lymphocytic bronchiolitis). However, interest in histopathology was really rekindled by observations of a primarily restrictive form of allograft dysfunction associated with an alternative form of fibrotic pulmonary remodeling. These observations eventually led to the definition of a restrictive variant of CLAD in 2011, restrictive allograft syndrome (RAS), an entity with its own specific clinical, radiologic, and histologic characteristics. As BO may also occur in RAS as a co-injury pattern, a fibrous alveolar obstruction with prominent elastic fiber deposition referred to as alveolar fibroelastosis (AFE), has been acknowledged as the main defining histomorphological feature. While lungs from patients with BOS typically show signs of airtrapping in computed tomography (CT) scans and by definition present with a strictly obstructive pulmonary function defect, patients with RAS show persistent radiological opacities and functional signs of restriction (decrease in total lung capacity ≥10% or FVC ≥20% compared to baseline).

Based on these observations, the term CLAD has been (re-)implemented as an umbrella term, encompassing all subforms of chronic pulmonary graft failure. The more prevalent BOS subgroup (65%-75% of CLAD patients) has a median survival postdiagnosis of 3-5 years, while the less frequent RAS form (25%-35% of CLAD patients) shows an even worse prognosis limited to only 0.5-1.5 years. Although clinically well defined, major gaps in our understanding of CLAD remain, including the relationship between BOS, RAS, and antibody-mediated rejection (AMR). AMR is considered a process of immune activation, whereby B cells and plasma cells produce antibodies against donor antigens, a process clinically and morphologically well defined in kidney and heart transplant recipients, but poorly characterized in LTx recipients. The reported incidence of pulmonary AMR is highly variable, but unequivocally associated with a poor outcome.

The process of correlating histological and molecular injury patterns with distinct clinical forms of CLAD is still ongoing and has been recognized to be of major prognostic importance. Therefore, in this review we will discuss the different presentations of CLAD, focusing on histopathological and molecular aspects of BOS, RAS, and AMR.
Here, the amphiregulin-hyaluronan axis is considered a major driving force in the epithelial response to injury as it accumulates in the affected epithelium in fibrotic airways. While amphiregulin, an epidermal growth factor receptor ligand, induces an increased proliferative capacity, an initial mucous hyperplasia, and altered ciliated cell differentiation in airway basal cells, hyaluronan regulates the subsequent innate inflammatory responses by releasing cytokines, chemokines, and growth factors attracting predominantly neutrophils and macrophages. As this inflammatory response to injury spirals out of control, (myo-)fibroblasts from different sources accumulate, including epithelial to mesenchymal transition, recruitment of fibrocyte progenitors from the peripheral blood, accumulation of resident fibroblasts, while a diminished/alteration in the microvasculature has also been put forward as one of the main mechanisms towards BO development.

BO manifests in various clinical settings, and some studies compared BO post-LTx to BO post–hematopoietic stem cell transplantation (HSCT). Although both patient groups share an allo-immune setting with additional infectious triggers, patients after HSCT lack the epithelial injury due to cold and warm ischemia associated with LTx. However, airway morphometric comparison revealed no differences between BO post-lung transplant and BO post-HSCT, while the molecular signatures consisting mostly of matrix remodeling genes were also very similar in both conditions, resulting in the conclusion that “BO is essentially BO” whatever the underlying cause.

Given the strong signature of differentially expressed genes associated with BO, their analysis is thought to be usable for an early prediction and thus an earlier diagnosis of CLAD. In this respect, molecular profiling of transbronchial biopsies revealed a signature based on bone morphogenetic protein 4, interleukin-6, matrix metalloproteinases, mothers against decapentaplegic homolog 1, and thrombospondin1 as a reliable tool to separate patients with CLAD from stable patients. Signatures that have proven to be valid in detecting rejection in other solid organ transplants have been found to be generalizable in lung transplant biopsies for detecting T cell–mediated rejection, AMR, and other forms of lung injury. However, it yet remains to be confirmed whether these molecular signatures are specifically valid for BOS or even RAS, given the aforementioned low sensitivity of transbronchial biopsies for the diagnosis of CLAD and also given that there are likely organ-specific mechanisms of rejection. Recently, mucosal biopsies, which are not routinely used in clinical diagnostics, have been shown to express a reasonably similar molecular signature to transbronchial biopsies and could therefore potentially be of use to detect and differentiate additional response-to-injury patterns. Lastly, the diagnostic use of cryobiopsies in lung allografts increases the amount of tissue obtained and...
thus potentially improves the diagnostic yield. However, their universal implementation should be critically discussed considering the increased risks of bleeding and air leakage.32

3 | RESTRICTIVE ALLOGRAFT SYNDROME

Following the first descriptions of lung injury patterns after LTx other than classical BOS11,12 and the subsequent original description of RAS with its characteristic scarring of the alveolar parenchyma,13 a number of papers addressed the actual morphological presentation of RAS. Initially, the main histopathological/radiological manifestation was thought to be pleuroparenchymal fibroelastosis (PPFE), defined by subpleural collagen deposition with a thickening of the alveolar septal elastic network, specifically affecting the (sub)pleural and paraseptal pulmonary compartment, especially in the upper lobes of the lung.34 However, in a further histopathological analysis of 21 RAS cases, von der Thüsen et al found PPFE only in 10 of 21 cases, while patterns of nonspecific interstitial pneumonia, fibrinous exudates, and emphysema were also described, similar to findings post-HSCT.33 PPFE, however, is a terminology mostly utilized to describe a radiologic pattern, whereas the more accurate histologic description of the observed pattern of predominant subpleural and paraseptal congenous obliteration of the alveoli with elastosis is AFE. Analogous to BO, AFE could also be shown to be a general reaction to injury, which can arise due to viral or bacterial infection, but also following acute AMR, leading to a sequence of vascular and epithelial injury, intra-alveolar fibrinous exudation, aberrant macrophage accumulation and activation, failed fibrin degradation, and ultimately fully developed AFE.25,32 The relevance of fibrin deposition is provided by a study of Paraskeva et al, who demonstrated that acute fibri-

![Pathophysiological mechanisms of alveolar fibroelastosis (AFE) in restrictive allograft syndrome. A, A multitude of potential injuries affect the alveoli. B, Antibody binding in the pulmonary capillaries or persistent injury to the alveoli lead to a disturbance of the air-blood interface and leakage of fibrin into the alveoli. C, This leads to an additional inflammatory response in which mainly macrophages seek to clear the fibrin, but fail to do, inducing an additional humoral response and recruitment of (myo-)fibroblasts. D, Finally, alveoli are being completely obliterated by (myo-)fibroblasts, resulting in the fully developed AFE. E, Elastica staining demonstrating paraseptal intra-alveolar fibrosis with septal elastosis. F, H&E showing consolidated fibrosis and obliteratorive airway remodeling with complete loss of the alveolar parenchyma and scattered lymphocytic aggregates.](https://wileyonlinelibrary.com)
partial—overlap between BOS and RAS. The relative number of airways per generation affected by BO is, however, lower in RAS compared to BOS, with 30%-40% of airways showing BO from generation 6 onwards. Next to these airways with BO, the absolute number of airways visible on CT was also lower in RAS due to alveolar fibrotic overgrowth extending into the terminal bronchioles.41

More comprehensive and preferably multicenter studies specifically assessing early histologic changes and possible predictive patterns in transbronchial biopsies of RAS patients are certainly needed. Further molecular signature studies should also focus on separating BOS from RAS early on. A common rejection gene expression panel that has been validated especially to detect all forms of rejection in kidney transplants found differences in CXCL-9 and CXCL-10 in RAS tissue vs controls, but failed to identify molecular differences between BOS and controls.42

The common denominator of all these studies is probably that all focus is in some way on the clinical RAS phenotype and larger, multicenter trials are needed to further dissect the more subtle differences with regard to underlying mechanisms, but also patient outcome. The recently published International Society for Heart and Lung Transplantation (ISHLT) consensus provides the correct framework for patient selection and recruitment to conduct such detailed studies by providing universal guidelines for patient diagnosis.15,16

4 | ANTIBODY-MEDIATED REJECTION

An expert panel of the ISHLT established key diagnostic criteria for pulmonary AMR representing an under-recognized cause of CLAD. In that report, they acknowledged the lack of a proper definition of chronic AMR (cAMR) as a major limitation and one of the key areas for further research. While clinically evident AMR is associated with increased risk of CLAD, there is also evidence that subclinical AMR may be a precursor to CLAD. Diagnostic criteria for AMR include the presence of graft dysfunction, donor-specific HLA antibodies (DSA), aberrant lung histology with or without concurrent C4d deposition, a breakdown product from the complement system, within the graft leading to a “definite,” “probable,” or “possible” AMR diagnosis. In lung tissue specimens, common histologic findings include neutrophil margination, neutrophilic
capillaritis and arteritis, and alveolar septal widening, although all of these may also be seen in other forms of lung injury\textsuperscript{17,43} (Figure 3). A Banff study further correlated the presence of capillary inflammation, acute lung injury, and endothelialitis with the presence of circulating DSA,\textsuperscript{44} while other (nonspecific) findings in lungs with AMR include microvascular thrombi, alveolar hemorrhage, accumulation of neutrophils within adjacent alveolar airspaces, but also persistent or recurrent high-grade acute cellular rejection, lymphocytic bronchiolitis, and BO.\textsuperscript{45}

The role for C4d in the diagnosis of AMR remains particularly questionable, as there are considerable technical and interpretation issues with C4d immunohistochemistry/imunofluorescence in pulmonary specimens, including poor reproducibility and prominent background staining.\textsuperscript{46} The general consensus is that diffuse (>50%) C4d staining of the interstitial alveolar capillaries appears to be a strong indicator of acute (clinical) AMR, although in general this is considered very uncommon. Indeed, C4d particularly lacks the sensitivity to detect subclinical episodes of AMR.\textsuperscript{44,46,47} This has conclusively been proven by Aguilar and colleagues, who compared a large series of C4d\textsuperscript{+}, probable AMR and C4d\textsuperscript{−}, definite AMR cases. While the incidence of neutrophilic capillaritis was higher in the C4d\textsuperscript{+} group, there was no difference between the C4d\textsuperscript{+} and C4d\textsuperscript{−} group regarding other histological and clinical characteristics, with a similar (poor) freedom from CLAD and survival.\textsuperscript{48}

Besides the technical limitation of the C4d staining and limitation of C4d as a biomarker, it is now well accepted that AMR relies mainly on 3 different, nonexclusive mechanisms. The first is complement dependent, leading to split products liberation such as C3a and C5a (highly chemoattractive) and in few cases to membrane attack complex with subsequent cell lysis. The 2 others are noncomplement dependent, involving either antibody-dependent cellular cytotoxicity through NK cells,\textsuperscript{49,50} neutrophil, and macrophages\textsuperscript{51} or agonist role of HLA DSA through fixation to Class I and Class II MHC molecules leading to endothelial cell proliferation and remodeling.\textsuperscript{32}

Therefore, the diagnosis of pulmonary AMR requires a comprehensive multidisciplinary approach, including clinical, serological, and histopathological information.

## 5 | GRAFT FAILURE: ONE SIZE FITS ALL?

There seems to be considerable mechanistic and clinical overlap between BOS, RAS, and cAMR. BO lesions are observed in both BOS and RAS. Also in AMR, their presence is considered a histologic abnormality consistent with AMR. Therefore, BO appears to be an injury pattern due to a variety of both immunological and nonimmunological triggers leading to CLAD. Furthermore, patients can switch clinically from a BOS to a RAS phenotype (or vice versa) during their posttransplant trajectory (mixed CLAD).\textsuperscript{16} Similarly, the presence of DSA is an important indicator of AMR, but at the same time also forms a risk factor for both BOS and RAS.\textsuperscript{38,39} Therefore, the potential interrelation between RAS and cAMR deserves further attention. Patients surviving an acute AMR episode almost exclusively develop RAS later on.\textsuperscript{53} Moreover, in addition to the fact that a significant proportion of RAS patients show evidence of circulating DSA, recent evidence also suggests that DSA can be graft resident in the absence of circulating DSA, even with spatial heterogeneity within the lung.\textsuperscript{54} Moreover, the concurrent presence of graft resident and circulating DSA correlates with poor transplant outcome.\textsuperscript{55} Given these similarities and considering the fact that they are not mutually exclusive, it seems plausible that BOS-RAS and cAMR form an actual spectrum of injury and remodeling and that, depending on the site and the severity of injury (bronchial, alveolar, or vascular), different inadequate repair processes are at fault for the respective clinical manifestations.

In the end, "tissue remains the (main) issue," as we are still limited in our knowledge of the actual mechanisms of all late forms of posttransplant graft failure. Analysis of bronchoalveolar lavages, albeit clinically useful, has so far not proven to enable reliable differential diagnosis in CLAD phenotypes. Current therapies for CLAD such as extracorporeal photopheresis, montelukast, pirfenidone, or nintedanib at best slow down the progression.\textsuperscript{56} Therefore, more comprehensive investigation of the processes involved will certainly improve our understanding of these diseases, and will bring us 1 step closer to adequate therapies, which are desperately needed.

## ACKNOWLEDGMENTS

SEV is a postdoctoral fellow of the FWO (12G8718N, V441019N) and acknowledges KU Leuven for their financial support (C24/18/073). DJ is supported by the grant of the European Research Council (ERC); European Consolidator Grant, XHale (ref. no.771883).

## DISCLOSURE

The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

## DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

## ORCID

Stijn E. Verleden https://orcid.org/0000-0002-9656-5844

## REFERENCES

1. Venuta F, Van Raemdonck D. History of lung transplantation. J Thorac Dis. 2017;9(12):5458-5471.
2. Derom FR, Barbier F, Ringoir S, et al. Ten-month survival after lung homotransplantation in man. J Thorac Cardiovasc Surg. 1971;61(6):835-846.
3. Epler GR, Colby TV. The spectrum of bronchiolitis obliterans. Chest. 1983;83(2):161-162.
4. Ralph DD, Springmeyer SC, Sullivan KM, Hackman RC, Storb R, Thomas ED. Rapidly progressive air-flow obstruction in marrow transplant recipients. Possible association between obliterative bronchiolitis and chronic graft-versus-host disease. Am Rev Respir Dis. 1984;129(4):641-644.
5. Burke CM, Theodore J, Dawkins KD, et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest. 1984;86(6):824-829.
6. Glanville AR, Baldwin JC, Burke CM, Theodore J, Robin ED. Obliterative bronchiolitis after heart-lung transplantation: apparent arrest by augmented immunosuppression. *Ann Intern Med.* 1987;107(3):300-304.

7. Tazelaar HD, Yousem SA. The pathology of combined heart-lung transplantation: an autopsy study. *Hum Pathol.* 1988;19(12):1403-1416.

8. Kramer MR, Stoeck C, Whang JL, et al. The diagnosis of obliterative bronchiolitis after heart-lung and lung transplantation: low yield of transbronchial lung biopsy. *J Heart Lung Transplant.* 1993;12(4):675-681.

9. Cooper JD, Billingham M, Egan T, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. *J Heart Lung Transplant.* 1993;12(5):713-716.

10. Verleden S, Vandermeulen E, Rottens D, et al. Neutrophilic reversible allograft dysfunction (NRAD) and restrictive allograft syndrome (RAS). *Semin Respir Crit Care Med.* 2013;34(3):352-360.

11. Pakhale SS, Hadjiliadis D, Howell DN, et al. Upper lobe fibrosis: a novel manifestation of chronic allograft dysfunction in lung transplantation. *J Heart Lung Transplant.* 2005;24(9):1260-1268.

12. Konen E, Weisbrod GL, Pakhale S, Chung T, Paul NS, Hutcheon MA. Fibrosis of the upper lobes: a newly identified late-onset complication after lung transplantation? *AJR Am J Roentgenol.* 2003;181(6):1539-1543.

13. Sato M, Waddell TK, Wagnet U, et al. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. *J Heart Lung Transplant.* 2011;30(7):735-742.

14. Ofek E, Sato M, Saito T, et al. Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis. *Mod Pathol.* 2013;26(3):350-356.

15. Glanville AR, Verleden GM, Todd ED, et al. Chronic lung allograft dysfunction: definition and update of restrictive allograft syndrome-A consensus report from the Pulmonary Council of the ISHLT. *J Heart Lung Transplant.* 2019;38(5):483-492.

16. Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT. *J Heart Lung Transplant.* 2019;38(5):493-503.

17. Levine DJ, Glanville AR, Aboyoun C, et al. Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant.* 2016;35(4):397-406.

18. Verleden SE, Vasilescu DM, Willems S, et al. The site and nature of airway obstruction after lung transplantation. *Am J Respir Crit Care Med.* 2014;189(3):292-300.

19. Colombat M, Holfianjainaina S, Hirschi S, Mal H, Stern M. Histologic reconstruction of bronchiolar lesions in lung transplant patients with bronchiolitis obliterans syndrome. *Am J Surg Pathol.* 2014;38(8):1157-1158.

20. Swatek AM, Lynch TJ, Crooke AK, et al. Depletion of Airway submucosal glands and TP63+KRT5+ basal cells in obliterative bronchiolitis. *Am J Respir Crit Care Med.* 2018;197(8):1045-1057.

21. Kuehnel M, Maegel L, Vogel-Claussen J, Robertus JL, Jonigk D. Airway remodeling in the transplanted lung. *Cell Tissue Res.* 2017;367(3):663-675.

22. Todd JL, Wang X, Sugimoto S, et al. Hyaluronan contributes to bronchiolitis obliterans syndrome and stimulates lung allograft rejection through activation of innate immunity. *Am J Respir Crit Care Med.* 2014;189(5):556-566.

23. Todd JL, Kelly FL, Nagler A, et al. Amphiregulin contributes to airway remodeling in chronic allograft dysfunction after lung transplantation. *Am J Transplant.* 2020;20(3):825-833.

24. Borthwick LA, Suwara MI, Carnell SC, et al. *Pseudomonas aeruginosa* induced airway epithelial injury drives fibroblast activation: a mechanism in chronic lung allograft dysfunction. *Am J Transplant.* 2016;16(6):1751-1765.

25. LaPar DJ, Burdick MD, Emamnia A, et al. Circulating fibrocyes correlate with bronchiolitis obliterans syndrome development after lung transplantation: a novel clinical biomarker. *Ann Thorac Surg.* 2011;92(2):470-477.

26. Nicolls MR, Hsu JL, Jiang X. Microvascular injury after lung transplantation. *Curr Opin Organ Transplant.* 2016;21(3):279-284.

27. Jonigk D, Rath B, Borchert P, et al. Comparative analysis of morphological and molecular motifs in bronchiolitis obliterans and alveolar fibroelastosis after lung and stem cell transplantation. *J Pathol Clin Res.* 2017;3(1):17-28.

28. Jonigk D, Izykowsi N, Rische J, et al. Molecular profiling in human pulmonary allografts to predict chronic lung allograft dysfunction. *Am J Pathol.* 2015;185(12):3178-3188.

29. Halloran PF, Venner JM, Madl-Hommes KE, et al. Review: the transcripts associated with organ allograft rejection. *Am J Transplant.* 2018;18(4):785-795.

30. Halloran KM, Parkes MD, Chang J, et al. Molecular assessment of rejection and injury in lung transplant biopsies. *J Heart Lung Transplant.* 2019;38(5):504-513.

31. Halloran K, Parkes MD, Timofte IL, et al. Molecular phenotyping of rejection-related changes in mucosal biopsies from lung transplants. *Am J Transplant.* 2019;20(4):954-966.

32. Montero MA, de Gracia J, Culebras Amigo M, et al. The role of transbronchial cryobiopsy in lung transplantation. *Histopathology.* 2018;73(4):593-600.

33. Meignin V, Thivolet-Beuzi F, Kambouchner M, et al. Lung histopathology of non-infectious pulmonary complications after allo-geneic haematopoietic stem cell transplantation. *Histopathology.* 2018;73(5):832-842.

34. Paraskeva M, McLean C, Ellis S, et al. Acute fibroid organizing pneumonia after lung transplantation. *Am J Respir Crit Care Med.* 2013;187(12):1360-1368.

35. Sato M, Hwang DM, Ohmori-Matsuda K, et al. Revisiting the pathologic finding of diffuse alveolar damage after lung transplantation. *J Heart Lung Transplant.* 2012;31(4):354-363.

36. Vandermeulen E, Lammertyn E, Verleden SE, et al. Immunological diversity in phenotypes of chronic lung allograft dysfunction: a comprehensive immunohistochemical analysis. *Transpl Int.* 2017;30(2):134-143.

37. Watanabe T, Martinu T, Chrusciński A, et al. A B cell-dependent pathway drives chronic lung allograft rejection after ischemia-reperfusion injury in mice. *Am J Transplant.* 2019;19(12):3377-3389.

38. Koutsokera A, Royer PJ, Antonietti JP, et al. Development of a multivariate prediction model for early-onset bronchiolitis obliterans syndrome and restrictive allograft syndrome in lung transplantation. *Front Med (Lausanne).* 2017:4:109.

39. Verleden SE, Vanaudenaerde BM, Emonds M-P, et al. Donor- and -nonspecific HLA antibodies and outcome post lung transplantation. *Eur J Resp J.* 2017;50(5):1701248.

40. Montero MA, Osadolor T, Khiroya R, et al. Restrictive allograft syndrome and idiopathic pleuroparenchymal fibroelastosis: do they really have the same histology? *Histopathology.* 2017;70(7):1107-1113.

41. Verleden SE, Vasilescu DM, McDonough JE, et al. Linking clinical phenotypes of chronic lung allograft dysfunction to changes in lung structure. *Eur J Resp J.* 2015;46(5):1430-1439.

42. Sacreas A, Yang JYC, Vanaudenaerde BM, et al. The common rejection module in chronic rejection post lung transplantation. *PLoS ONE.* 2018;13(10):e0205107.

43. Calabrese F, Hirschi S, Neil D, et al. Alveolar septal widening as an “alert” signal to look into lung antibody-mediated rejection: a multicenter pilot study. *Transplantation.* 2019;103(11):2440-2447.
44. Wallace WD, Li N, Andersen CB, et al. Banff study of pathologic changes in lung allograft biopsy specimens with donor-specific antibodies. *J Heart Lung Transplant*. 2016;35(1):40-48.
45. Roux A, Levine DJ, Zeeven A, et al. Banff Lung Report: current knowledge and future research perspectives for diagnosis and treatment of pulmonary antibody-mediated rejection (AMR). *Am J Transplant*. 2019;19(1):21-31.
46. Roden AC, Maleszewski JI, Yi ES, et al. Reproducibility of Complement 4d deposition by immunofluorescence and immunohistochemistry in lung allograft biopsies. *J Heart Lung Transplant*. 2014;33(12):1223-1232.
47. Ngo C, Danel C, Duong-Quy SY, et al. C4d detection and histological patterns in the diagnosis of antibody-mediated rejection after lung transplantation: a single-centre study. *Histopathology*. 2019;74(7):988-996.
48. Aguilar PR, Carpenter D, Ritter J, et al. The role of C4d deposition in the diagnosis of antibody-mediated rejection after lung transplantation. *Am J Transplant*. 2018;18(4):936-944.
49. Haas M. An updated Banff schema for diagnosis of antibody-mediated rejection in renal allografts. *Curr Opin Organ Transplant*. 2014;19(3):315-322.
50. Orandi BJ, Alachkar N, Kraus ES, et al. Presentation and outcomes of C4d-negative antibody-mediated rejection after kidney transplantation. *Am J Transplant*. 2016;16(1):213-220.
51. Thomas KA, Valenzuela NM, Reed EF. The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection. *Trends Mol Med*. 2015;21(5):319-329.
52. Valenzuela NM, Reed EF. Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies. *J Clin Invest*. 2017;127(7):2492-2504.
53. Roux A, Bendib Le Lan I, Holifanjaniaina S, et al. Antibody-mediated rejection in lung transplantation: clinical outcomes and donor-specific antibody characteristics. *Am J Transplant*. 2016;16(4):1216-1228.
54. Sacreas A, Taupin J-L, Emonds M-P, et al. Intragraft donor-specific anti-HLA antibodies in phenotypes of chronic lung allograft dysfunction. *Eur Respir J*. 2019;54(5):1900847.
55. Visentin J, Chartier A, Massara L, et al. Lung intragraft donor-specific antibodies as a risk factor for graft loss. *J Heart Lung Transplant*. 2016;35(12):1418-1426.
56. Benden C, Haughton M, Leonard S, Huber LC. Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: a systematic review. *J Heart Lung Transplant*. 2017;36(9):921-933.

**How to cite this article:** Verleden SE, Von der Thüsen J, Roux A, et al. When tissue is the issue: A histological review of chronic lung allograft dysfunction. *Am J Transplant*. 2020;20:2644–2651. [https://doi.org/10.1111/ajt.15864](https://doi.org/10.1111/ajt.15864)